LucilleAFerranteMD

Medical Director- Oncology/ Janssen Scientific Affairs

Dr. Ferrante is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Office
Janssen Scientific Affairs, LLC
800 Ridgeview Drive
Horsham, PA 19044
Phone+1 215-325-2696
Is this information wrong?

Medical University of South CarolinaFellowship, Pediatric Hematology/Oncology, 2003 - 2006
Tulane UniversityResidency, Pediatrics, 1998 - 2001
University of South Alabama College of MedicineClass of 1998

PubMed

47 citations
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, po...
Jacob D. Soumerai, Ai Ni, Mohamed Darif, Anil Londhe, Guan Xing, Yeung-Chul Mun, Neil E. Kay, Tait D. Shanafelt, Kari G. Rabe, John C. Byrd, Asher Chanan-Khan, Richard...> ;The Lancet. Haematology. 2019 Jul 1
To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma:
Peter Martin, Andre Goy, Radhakrishnan Ramchandren, Lucille Ferrante, Anil Londhe, Tracy McGowan, Nancy L. Bartlett> ;Journal of Oncology Pharmacy Practice. 2019 Feb 20

Lectures

Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018